- Home
- ICLK vs BTAI Comparison
ICLK vs BTAI Comparison
Compare ICLK & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLK
- BTAI
- Stock Information
- Founded
- ICLK 2009
- BTAI 2017
- Country
- ICLK Hong Kong
- BTAI United States
- Employees
- ICLK N/A
- BTAI N/A
- Industry
- ICLK Computer Software: Prepackaged Software
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- ICLK Technology
- BTAI Health Care
- Exchange
- ICLK Nasdaq
- BTAI Nasdaq
- Market Cap
- ICLK 29.1M
- BTAI 28.7M
- IPO Year
- ICLK 2017
- BTAI 2018
- Fundamental
- Price
- ICLK $8.58
- BTAI $0.36
- Analyst Decision
- ICLK
- BTAI Strong Buy
- Analyst Count
- ICLK 0
- BTAI 4
- Target Price
- ICLK N/A
- BTAI $5.00
- AVG Volume (30 Days)
- ICLK 110.3K
- BTAI 949.6K
- Earning Date
- ICLK 11-27-2024
- BTAI 11-14-2024
- Dividend Yield
- ICLK N/A
- BTAI N/A
- EPS Growth
- ICLK N/A
- BTAI N/A
- EPS
- ICLK N/A
- BTAI N/A
- Revenue
- ICLK $130,443,999.00
- BTAI $2,276,000.00
- Revenue This Year
- ICLK $26.49
- BTAI $164.86
- Revenue Next Year
- ICLK $12.11
- BTAI $69.74
- P/E Ratio
- ICLK N/A
- BTAI N/A
- Revenue Growth
- ICLK N/A
- BTAI 83.25
- 52 Week Low
- ICLK $1.03
- BTAI $0.35
- 52 Week High
- ICLK $8.76
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- ICLK 71.58
- BTAI 32.49
- Support Level
- ICLK $6.97
- BTAI $0.35
- Resistance Level
- ICLK $8.14
- BTAI $0.52
- Average True Range (ATR)
- ICLK 0.93
- BTAI 0.06
- MACD
- ICLK 0.13
- BTAI -0.00
- Stochastic Oscillator
- ICLK 96.22
- BTAI 2.92
About ICLK iClick Interactive Asia Group Limited
iClick Interactive Asia Group Ltd is an enterprise and marketing cloud Platform in China. It offers a consumer full lifecycle solution that addresses client's needs from traffic acquisition, customer relations management, and business decision optimization driven by data analytics in the retail era. It has two operating segments: Marketing Solutions, and Enterprise Solutions. Geographically, it derives the majority revenue from Mainland China and also has a presence in Hong Kong and other countries.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.